

SCHWARTZ ALICE N
Form 4
December 05, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
SCHWARTZ ALICE N

2. Issuer Name and Ticker or Trading Symbol
BIO RAD LABORATORIES INC
[BIO, BIOB]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
12/03/2012

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

HERCULES, CA 94547

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Bio-Rad A Common Stock					2,772,912	D	
Bio-Rad A Common Stock					34,311	I	By Trust
Bio-Rad B Common Stock	12/03/2012		M		8,000 (1)	A	\$ 36
					489,436	(2)	D

Edgar Filing: SCHWARTZ ALICE N - Form 4

Bio-Rad B Common Stock	12/03/2012	M	<u>7,608</u> (1)	A	\$ 53.5	497,044	D	
Bio-Rad B Common Stock	12/03/2012	M	<u>8,227</u> (1)	A	\$ 56.4	505,271	D	
Bio-Rad B Common Stock	12/03/2012	M	<u>8,413</u> (1)	A	\$ 63	513,684	D	
Bio-Rad B Common Stock	12/03/2012	M	<u>4,000</u> (1)	A	\$ 75	517,684	D	
Bio-Rad B Common Stock	12/03/2012	M	<u>3,000</u> (1)	A	\$ 88.48	520,684	D	
Bio-Rad B Common Stock	12/03/2012	M	<u>2,000</u> (1)	A	\$ 75.38	522,684	D	
Bio-Rad B Common Stock	12/03/2012	M	<u>1,000</u> (1)	A	\$ 84.57	523,684	D	
Bio-Rad B Common Stock	12/03/2012	F	24,014	D	\$ 104.85	499,670	D	
Bio-Rad B Common Stock	12/03/2012	G	720	D	\$ 0	498,950	D	
Bio-Rad B Common Stock						4,060,054	I	By Blue Raven Partners, L.P. ⁽³⁾
Bio-Rad B Common Stock						41,176	I	By DANSA Partners Limited ⁽⁴⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SCHWARTZ ALICE N - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 36	12/03/2012		M	8,000	<u>(5)</u> 02/05/2013	Bio-Rad B Common Stock	8,000	
Non-Qualified Stock Option (right to buy)	\$ 53.5	12/03/2012		M	7,608	<u>(6)</u> 02/04/2014	Bio-Rad B Common Stock	7,608	
Non-Qualified Stock Option (right to buy)	\$ 56.4	12/03/2012		M	8,227	<u>(7)</u> 02/09/2015	Bio-Rad B Common Stock	8,227	
Non-Qualified Stock Option (right to buy)	\$ 63	12/03/2012		M	8,413	<u>(8)</u> 04/03/2016	Bio-Rad B Common Stock	8,413	
Non-Qualified Stock Option (right to buy)	\$ 75	12/03/2012		M	4,000	<u>(9)</u> 08/01/2017	Bio-Rad B Common Stock	4,000	
Non-Qualified Stock Option (right to buy)	\$ 88.48	12/03/2012		M	3,000	<u>(10)</u> 06/11/2018	Bio-Rad B Common Stock	3,000	
Non-Qualified Stock Option (right to buy)	\$ 75.38	12/03/2012		M	2,000	<u>(11)</u> 06/10/2019	Bio-Rad B Common Stock	2,000	
Non-Qualified Stock Option (right to buy)	\$ 84.57	12/03/2012		M	1,000	<u>(12)</u> 09/08/2020	Bio-Rad B Common Stock	1,000	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SCHWARTZ ALICE N C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE HERCULES, CA 94547	X	X		

Signatures

Alice N.
Schwartz

12/05/2012

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) The stock option exercise reported is the exercise of derivative securities acquired upon the death of the reporting person's spouse, David Schwartz, former Chairman of the Board of Bio-Rad Laboratories, Inc. and beneficial owner of more than 10% of the Company's Common Stock.
 - (2) 1,002 unvested restricted stock Class B shares held by the reporting person's late spouse, David Schwartz, were forfeited as of the date of his death, April 1, 2012.
 - (3) The shares are held by a limited partnership of which the reporting person is a limited and general partner.
 - (4) The shares are held by a limited partnership of which the reporting person is a general partner.
 - (5) The stock option became exercisable in five equal annual installments beginning on February 5, 2004.
 - (6) The stock option became exercisable in five equal annual installments beginning on February 4, 2005.
 - (7) The stock option became exercisable in five equal annual installments beginning on February 9, 2006.
 - (8) The stock option became exercisable in five equal annual installments beginning on April 3, 2007.
 - (9) The stock option became exercisable in five equal annual installments beginning on August 1, 2008.
 - (10) The stock option became exercisable in five equal annual installments beginning on June 11, 2009.
 - (11) The stock option became exercisable in five equal annual installments beginning on June 10, 2010.
 - (12) The stock option became exercisable in five equal annual installments beginning on September 8, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.